Examining metastatic lymph nodes in each part of the stomach's mesentery during gastrectomy
The Clinical Significance of Examining Metastatic Lymph Nodes in Respective Gastric Mesenteries in the Gastric Cancer Patients Who Received D2 Lymphadenectomy Plus Complete Mesogastric Excision
This project will see if the number and location of metastatic lymph nodes across the six stomach mesenteries predict outcomes for adults undergoing D2 plus complete mesogastric excision for gastric cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | First Affiliated Hospital of Zhejiang University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT07139418 on ClinicalTrials.gov |
What this trial studies
This observational study enrolls adults with primary gastric adenocarcinoma (cT2–4aN0–3M0) who undergo gastrectomy with D2 lymphadenectomy plus complete mesogastric excision at The First Affiliated Hospital, Zhejiang University. Investigators will examine the presence of metastatic lymph nodes within each of six predefined gastric mesenteries and record how many mesenteries are involved. They will correlate mesentery involvement and number of metastatic mesenteries with standard TNM staging and patient outcomes to determine prognostic value. Key exclusions include prior neoadjuvant therapy, prior upper abdominal surgery, total or proximal gastrectomy, BMI >30, and other concurrent malignancies.
Who should consider this trial
Good fit: Adults aged 18–84 with primary gastric adenocarcinoma staged cT2–4aN0–3M0 who are planned for gastrectomy with D2 lymphadenectomy plus complete mesogastric excision, ASA class I–III, and who have not received neoadjuvant therapy.
Not a fit: Patients with cT4b or distant metastases, BMI over 30, prior neoadjuvant therapy or prior upper abdominal surgery, those undergoing total or proximal gastrectomy, or with other malignancies are not likely to benefit or be eligible.
Why it matters
Potential benefit: If successful, this could allow more precise prognosis and help guide adjuvant treatment and follow‑up based on which mesenteries contain metastatic nodes.
How similar studies have performed: While anatomical nodal mapping has been explored historically, specifically counting metastatic gastric mesenteries as a prognostic marker is relatively novel and not yet broadly validated.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Aged older than 18 years and younger than 85 years 2. Primary gastric adenocarcinoma confirmed by preoperative pathology result 3. cT2-4aN0-3M0 at preoperative evaluation according to the American Joint 8 Committee on Cancer (AJCC) Cancer Staging Manual 8th Edition 4. Patients who received gastrectomy with D2 lymphadenectomy plus complete mesogastric excision 5. American Society of Anesthesiologists (ASA) class I, II, or III 6. Written informed consent Exclusion Criteria: 1. Negative preoperative biopsy 2. Too late tumour stage or metastasis (cT4b/M1) 3. BMI\>30 kg/m2 4. Total gastrectomy or proximal gastrectomy 5. previous neoadjuvant chemotherapy or radiotherapy 6. Previous upper abdominal surgery 7. Combined with other malignant diseases 8. Reject operation
Where this trial is running
Hangzhou, Zhejiang
- Department of Gastrointestinal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine — Hangzhou, Zhejiang, China (Recruiting)
Study contacts
- Study coordinator: Tao Wang, Ph.d
- Email: 15002740874@163.com
- Phone: +86-197-068-25286
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.